1.Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 2010;363(5):411–22.
2.Walboomers, JM, Jacobs, MV, Manos, MM, Bosch, FX, Kummer, JA, Shah, KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 1999;189(1):12–19.
3.Wiemann, B, Starnes, CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology and Therapeutics, 1994;64(3):529–64.
4.Coley, WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proceedings of the Royal Society of Medicine, 1910;3(Surg Sect):1–48.
5.Burnet, FM. The concept of immunological surveillance. Progress in Experimental Tumor Research, 1970;13:1–27.
6.Finke, LH, Wentworth, K, Blumenstein, B, Rudolph, NS, Levitsky, H, Hoos, A. Lessons from randomized phase III studies with active cancer immunotherapies – outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine, 2007;25 Suppl 2:B97–B109.
7.Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Science of the United States of America, 1993;90(8):3539–43.
8.Hanayama, R, Tanaka, M, Miwa, K, Shinohara, A, Iwamatsu, A, Nagata, S. Identification of a factor that links apoptotic cells to phagocytes. Nature, 2002;417(6885):182–7.
9.Jinushi, M, Nakazaki, Y, Dougan, M, Carrasco, DR, Mihm, M, Dranoff, G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. Journal of Clinical Investigation, 2007;117(7):1902–13.
10.van der Bruggen, P, Traversari, C, Chomez, P, Lurquin, C, De Plaen, E, Van den Eynde, B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991;254(5038):1643–7.
11.Cormier, JN, Salgaller, ML, Prevette, T, Barracchini, KC, Rivoltini, L, Restifo, NP, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer Journal from Scientific American, 1997;3(1):37–44.
12.Marchand, M, van Baren, N, Weynants, P, Brichard, V, Dreno, B, Tessier, MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. International Journal of Cancer/Journal International du Cancer, 1999;80(2):219–30.
13.Schumacher, T, Bunse, L, Pusch, S, Sahm, F, Wiestler, B, Quandt, J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014;512:324–7.
14.Izumoto, S, Tsuboi, A, Oka, Y, Suzuki, T, Hashiba, T, Kagawa, N, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. Journal of Neurosurgery, 2008;108(5):963–71.
15.Yajima, N, Yamanaka, R, Mine, T, Tsuchiya, N, Homma, J, Sano, M, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clinical Cancer Research, 2005;11(16):5900–11.
16.Sampson, JH, Archer, GE, Mitchell, DA, Heimberger, AB, Herndon, JE, 2nd, Lally-Goss, D, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics, 2009;8(10):2773–9.
17.Sampson, JH, Heimberger, AB, Archer, GE, Aldape, KD, Friedman, AH, Friedman, HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 2010;28(31):4722–9.
18.Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, Schreiber, RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002;3(11):991–8.
19.Fecci, PE, Sampson, JH. Clinical immunotherapy for brain tumors. Neuroimaging Clinics of North America, 2002;12(4):641–64.
20.Gedeon, PC, Riccione, KA, Fecci, PE, Sampson, JH. Antibody-based immunotherapy for malignant glioma. Seminars in Oncology, 2014;41(4):496–510.
21.Bartels, U, Wolff, J, Gore, L, Dunkel, I, Gilheeney, S, Allen, J, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology, 2014;16(11):1554–9.
22.Nitta, T, Sato, K, Yagita, H, Okumura, K, Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 1990;335(8686):368–71.
23.Choi, BD, Kuan, CT, Cai, M, Archer, GE, Mitchell, DA, Gedeon, PC, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Science of the United States of America, 2013;110(1):270–5.
24.Fecci, PE, Heimberger, AB, Sampson, JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clinical Cancer Research, 2014;20(22):5620–9.
25.Fecci, PE, Mitchell, DA, Archer, GE, Morse, MA, Lyerly, HK, Bigner, DD, et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology, 2003;64(1–2):161–76.
26.Holladay, FP, Heitz-Turner, T, Bayer, WL, Wood, GW. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. Journal of Neuro-Oncology, 1996;27(2):179–89.
27.Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 2000;92(3):205–16.
28.Hoos, A, Eggermont, AM, Janetzki, S, Hodi, FS, Ibrahim, R, Anderson, A, et al. Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute, 2010;102(18):1388–97.
29.O’Regan, KN, Jagannathan, JP, Ramaiya, N, Hodi, FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR American Journal of Roentgenology, 2011;197(2):W241–6.
30.Wolchok, JD, Hoos, A, O’Day, S, Weber, JS, Hamid, O, Lebbe, C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research, 2009;15(23):7412–20.
31.Sampson, JH, Crotty, LE, Lee, S, Archer, GE, Ashley, DM, Wikstrand, CJ, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Science of the United States of America, 2000;97(13):7503–8.
32.Heimberger, AB, Crotty, LE, Archer, GE, Hess, KR, Wikstrand, CJ, Friedman, AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical Cancer Reseach, 2003;9(11):4247–54.
33.Mehta, AI, Persson, O, Herndon, JE, Archer, GE, McLendon, R, Heimberger, AB, et al. Reply to M.S. Lesniak. Journal of Clinical Oncology, 2011;29(22):3105–6.
34.Britten, CM, Janetzki, S, van der Burg, SH, Huber, C, Kalos, M, Levitsky, HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunology, Immunotherapy: CII, 2011;60(1):15–22.
35.Galon, J, Pages, F, Marincola, FM, Thurin, M, Trinchieri, G, Fox, BA, et al. The immune score as a new possible approach for the classification of cancer. Journal of Translational Medicine, 2012;10:1.
36.Britten, CM, Janetzki, S, Ben-Porat, L, Clay, TM, Kalos, M, Maecker, H, et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunology, Immunotherapy: CII, 2009;58(10):1701–13.
37.Moodie, Z, Price, L, Janetzki, S, Britten, CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods in Molecular Biology, 2012;792:185–96.
38.Welters, MJ, Gouttefangeas, C, Ramwadhdoebe, TH, Letsch, A, Ottensmeier, CH, Britten, CM, et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunology, Immunotherapy: CII, 2012;61(7):967–78.
39.Yuan, J, Gnjatic, S, Li, H, Powel, S, Gallardo, HF, Ritter, E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America, 2008;105(51):20410–5.
40.Wilde, S, Sommermeyer, D, Leisegang, M, Frankenberger, B, Mosetter, B, Uckert, W, et al. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. Journal of Immunology, 2012;189(2):598–605.
41.Abrams, JS. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. In Coligan JE, Bierer BE (eds.) Current Protocols in Immunology. New York: John Wiley; 2001, Chapter 6, Unit 6 20.
42.Barrette, RW, Urbonas, J, Silbart, LK. Quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction. Clinical and Vaccine Immunology, 2006;13(7):802–5.
43.Chen, R, Lowe, L, Wilson, JD, Crowther, E, Tzeggai, K, Bishop, JE, et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clinical Chemistry, 1999;45(9):1693–4.
44.Vergati, M, Schlom, J, Tsang, KY. The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol, 2011;2011:182413.
45.Olson, BM, McNeel, DG. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Frontiers in Oncology, 2013;3:109.
46.Brunner, KT, Mauel, J, Cerottini, JC, Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology, 1968;14(2):181–96.
47.Betts, MR, Brenchley, JM, Price, DA, De Rosa, SC, Douek, DC, Roederer, M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. Journal of Immunological Methods, 2003;281(1–2):65–78.
48.Rubio, V, Stuge, TB, Singh, N, Betts, MR, Weber, JS, Roederer, M, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nature Medicine, 2003;9(11):1377–82.
49.Six, A, Mariotti-Ferrandiz, ME, Chaara, W, Magadan, S, Pham, HP, Lefranc, MP, et al. The past, present, and future of immune repertoire biology – the rise of next-generation repertoire analysis. Frontiers in Immunology, 2013;4:413.
50.Medawar, PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. British Journal of Experimental Pathology, 1948;29(1):58–69.
51.Mattiace, LA, Davies, P, Dickson, DW. Detection of Hla-Dr on microglia in the human brain is a function of both clinical and technical factors. American Journal of Pathology, 1990;136(5):1101–14.
52.Hickey, WF, Osborn, JP, Kirby, WM. Expression of Ia molecules by astrocytes during acute experimental allergic encephalomyelitis in the Lewis rat. Cellular Immunology, 1985;91(2):528–35.
53.Takamura, Y, Ikeda, H, Kanaseki, T, Toyota, M, Tokino, T, Imai, K, et al. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia, 2004;45(4):392–405.
54.Hickey, WF, Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science, 1988;239(4837):290–2.
55.Cserr, HF, Knopf, PM. Cervical lymphatics, the blood–brain barrier and the immunoreactivity of the brain: a new view. Immunology Today, 1992;13(12):507–12.
56.Yamada, S, Depasquale, M, Patlak, CS, Cserr, HF. Albumin outflow into deep cervical lymph from different regions of rabbit brain. American Journal of Physiology, 1991;261(4):H1197–204.
57.Bradbury, MW, Cserr, HF, Westrop, RJ. Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit. American Journal of Physiology, 1981;240(4):F329–36.
58.Cserr, HF, Harlingberg, CJ, Knopf, PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathology, 1992;2(4):269–76.
59.Hickey, WF, Hsu, BL, Kimura, H. T-lymphocyte entry into the central nervous system. Journal of Neuroscience Research, 1991;28:254–60.
60.Hickey, WF, Kimura, H. Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proceedings of the National Academy of Science of the United States of America, 1987;84:2082–6.
61.Wikstrand, CJ, Bigner, DD. Surface antigens of human glioma cells shared with normal adult and fetal brain. Cancer Research, 1979;39:3235.
62.Bigner, DD, Pitts, OM, Wikstrand, CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. Journal of Neurosurgery, 1981;55(1):32–42.
63.Fecci, PE, Mitchell, DA, Whitesides, JF, Xie, W, Friedman, AH, Archer, GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research, 2006;66(6):3294–302.
64.Dunn, GP, Fecci, PE, Curry, WT. Cancer immunoediting in malignant glioma. Neurosurgery, 2012;71(2):201–22; discussion 22–3.
65.Dunn, GP, Fecci, PE, Curry, WT. Cancer immunoediting in malignant glioma. Neurosurgery, 2012;71(2):201–23.
66.Roszman, TL, Brooks, WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol, 1980;39(2): 395–402.
67.Brooks, WH, Caldwell, HD, Mortara, RH. Immune responses in patients with gliomas. Surgical Neurology, 1974;2(6):419–23.
68.Young, HF, Sakalas, R, Kaplan, AM. Inhibition of cell-mediated immunity in patients with brain tumors. Surgical Neurology, 1976;5(1):19–23.
69.Mahaley, MS, Jr., Brooks, WH, Roszman, TL, Bigner, DD, Dudka, L, Richardson, S. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. Journal of Neurosurgery, 1977;46(4):467–76.
70.Brooks, WH, Roszman, TL, Mahaley, MS, Woosley, RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clinical and Experimental Immunology, 1977;29(1):61–6.
71.Roszman, TL, Brooks, WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clinical and Experimental Immunology, 1980;39(2):395–402.
72.Roszman, TL, Brooks, WH, Steele, C, Elliott, LH. Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. Journal of Immunology, 1985;985:1545–50.
73.Elliott, LH, Brooks, WH, Roszman, TL. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. Journal of Neurosurgery, 1987;67(2):231–6.
74.Ausiello, CM, Palma, C, Maleci, A, Spagnoli, GC, Amici, C, Antonelli, G, et al. Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. European Journal of Cancer and Clinical Oncology, 1991;1991:646–50.
75.Elliott, LH, Brooks, WH, Roszman, TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. Journal of Immunology, 1984;132(3):1208–15.
76.Elliott, L, Brooks, W, Roszman, T. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. Journal of the National Cancer Institute, 1987;78(5):919–22.
77.Morford, LA, Elliott, LH, Carlson, SL, Brooks, WH, Roszman, TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. Journal of Immunology, 1997;159(9):4415–25.
78.Bodmer, S, Strommer, K, Frei, K, Siepl, C, de Tribolet, N, Heid, I, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. Journal of Immunology, 1989;143(10):3222–9.
79.de Martin, R, Haendler, B, Hofer-Warbinek, R, Gaugitsch, H, Wrann, M, Schlusener, H, et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO Journal, 1987;6(12):3673–7.
80.Fontana, A, Hengartner, H, de Tribolet, N, Weber, E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. Journal of Immunology, 1984;132(4):1837–44.
81.Wrann, M, Bodmer, S, de Martin, R, Siepl, C, Hofer-Warbinek, R, Frei, K, et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO Journal, 1987;6(6):1633–6.
82.Li, MO, Flavell, RA. TGF-beta: a master of all T cell trades. Cell, 2008;134(3):392–404.
83.Torre-Amione, G, Beauchamp, RD, Koeppen, H, Park, BH, Schreiber, H, Moses HL, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proceedings of the National Academy of Sciences of the United States of America, 1990;87(4):1486–90.
84.Dix, AR, Brooks, WH, Roszman, TL, Morford, LA. Immune defects observed in patients with primary malignant brain tumors. Journal of Neuroimmunology, 1999;100(1–2):216–32.
85.Zou, JP, Morford, LA, Chougnet, C, Dix, AR, Brooks, AG, Torres, N, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. Journal of Immunology, 1999;162(8):4882–92.
86.Roussel, E, Gingras, MC, Grimm, EA, Bruner, JM, Moser, RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clinical and Experimental Immunology, 1996;105(2):344–52.
87.Wintterle, S, Schreiner, B, Mitsdoerffer, M, Schneider, D, Chen, L, Meyermann, R, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Reseach, 2003;63:7462–7.
88.Gershon, RK, Kondo, K. Infectious immunological tolerance. Immunology, 1971;21(6):903–14.
89.Braun, DP, Penn, RD, Flannery, AM, Harris, JE. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery, 1982;10(2):203–9.
90.El Andaloussi, A, Lesniak, MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-Oncology, 2006;8(3):234–43.
91.Mitchell, DA, Cui, X, Schmittling, RJ, Sanchez-Perez, L, Snyder, DJ, Congdon, KL, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood, 2011;118(11):3003–12.
92.El Andaloussi, A, Han, Y, Lesniak, MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. Journal of Neurosurgery, 2006;105(3):430–7.
93.Learn, CA, Fecci, PE, Schmittling, RJ, Xie, W, Karikari, I, Mitchell, DA, et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clinical Cancer Research, 2006;12(24):7306–15.
94.Sanchez-Perez, LA, Choi, BD, Archer, GE, Cui, X, Flores, C, Johnson, LA, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS ONE, 2013;8(3):e59082.
95.Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002;298(5594):850–4.
96.Dummer, W, Niethammer, AG, Baccala, R, Lawson, BR, Wagner, N, Reisfeld, RA, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. Journal of Clinical Investigation, 2002;110(2):185–92.
97.Asavaroengchai, W, Kotera, Y, Mule, JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proceedings of the National Academy of Science of the United States of America, 2002;99(2):931–6.
98.Sampson, JH, Aldape, KD, Archer, GE, Coan, A, Desjardins, A, Friedman, AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011;13(3):324–33.
99.Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 2012;12(4):252–64.
100.Peggs, KS, Quezada, SA, Chambers, CA, Korman, AJ, Allison, JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. Journal of Experimental Medicine, 2009;206(8):1717–25.
101.Hodi, FS, O’Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 2010;363(8):711–23.
102.Agarwalla, P, Barnard, Z, Fecci, P, Dranoff, G, Curry, WT, Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. Journal of Immunotherapy, 2012;35(5):385–9.
103.Fecci, PE, Ochiai, H, Mitchell, DA, Grossi, PM, Sweeney, AE, Archer, GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research, 2007;13(7):2158–67.
104.Margolin, K, Hamid, O, Lawrence, D, McDermott, D, Puzanov, I, Wolchok, JD, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncology, 2012;13(5): 459–65.
105.Brentjens, R, Yeh, R, Bernal, Y, Riviere, I, Sadelain, M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Molecular Therapy, 2010;18(4):666–8.
106.Sampson, JH, Choi, BD, Sanchez-Perez, L, Suryadevara, CM, Snyder, DJ, Flores, CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clinical Cancer Research, 2014;20(4):972–84.
107.Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008;321(5891):974–7.
108.Cobbs, CS, Harkins, L, Samanta, M, Gillespie, GY, Bharara, S, King, PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Research, 2002;62(12):3347–50.
109.Mitchell, DA, Xie, W, Schmittling, R, Learn, C, Friedman, A, McLendon, RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology, 2008;10(1):10–18.
110.Nair, SK, De Leon, G, Boczkowski, D, Schmittling, R, Xie, W, Staats, J, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clinical Cancer Research, 2014;20(10):2684–94.
111.Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008;321(5897):1807–12.
112.Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W, et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 2009;360(8):765–73.